Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

被引：6

作者：

Usmani, Saad Z. ^{[1
]}

Nahi, Hareth ^{[2
]}

Mateos, Maria-Victoria ^{[3
]}

Lokhorst, Henk M. ^{[4
]}

Chari, Ajai ^{[5
]}

Kaufman, Jonathan L. ^{[6
]}

Moreau, Philippe ^{[7
]}

Oriol, Albert ^{[8
]}

Plesner, Torben ^{[9
,10
,11
]}

Benboubker, Lotfi ^{[12
]}

Hellemans, Peter ^{[13
]}

Masterson, Tara ^{[14
]}

Clemens, Pamela L. ^{[15
]}

Ahmadi, Tahamtan ^{[15
]}

Liu, Kevin ^{[16
]}

San-Miguel, Jesus ^{[17
]}

机构：

[1] Levine Canc Inst Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[2] Karolinska Univ Hosp, Karolinska Inst, Div Hematol, Huddinge, Sweden

[3] Univ Hosp Salamanca IBSAL, Salamanca, Spain

[4] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[5] Tisch Canc Inst, Mt Sinai Sch Med, New York, NY USA

[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[7] Nantes Univ Hosp, Dept Hematol, Nantes, France

[8] HGTiP, Inst Catala Oncol, Barcelona, Spain

[9] Univ So Denmark, Vejle Hosp, Ctr Little Belt, Dept Hematol, Vejle, Denmark

[10] Vejle Hosp, Dept Hematol, Vejle, Denmark

[11] Univ So Denmark, Vejle, Denmark

[12] CHU Tours Hop Bretonneau, Tours, France

[13] Janssen Res & Dev, Beerse, Belgium

[14] Janssen Res & Dev, Spring House, PA USA

[15] Janssen Res & Dev, LLC, Spring House, PA USA

[16] Janssen Res & Dev, LLC, Raritan, NJ USA

[17] Clin Univ Navarra CIMA, IDISNA, Pamplona, Spain

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1149.1149

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1149

引用

页数：6

共 50 条

[41] A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TAK-169 in Patients With Relapsed or Refractory Multiple Myeloma
Kumar, Shaji
Mamuye, Admasu
Dabovic, Kristina
Wang, Jingyuan
Roy, Vivek
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S10 - S11
[42] Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Hutchings, Martin
Mous, Rogier
Clausen, Michael Roost
Johnson, Peter
Linton, Kim M.
Chamuleau, Martine E. D.
Lewis, David John
Balari, Anna Sureda
Cunningham, David
Oliveri, Roberto S.
Elliott, Brian
DeMarco, Dena
Azaryan, Ada
Chiu, Christopher
Li, Tommy
Chen, Kuo-mei
Ahmadi, Tahamtan
Lugtenburg, Pieternella J.
LANCET, 2021, 398 (10306): : 1157 - 1169
[43] A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
Sia, Hanlon
Tan, Peter T.
Richter, Joshua
Ho, Phoebe Joy
Cochrane, Tara
Quach, Hang
Dhakal, Binod
Proscurshim, Igor
Jiang, Tony
Mancino, Emaryn
Salhi, Yacine
Stefano, Sammicheli
Gudi, Girish
Garton, Andrew
Feldman, Eric J.
Spencer, Andrew
BLOOD, 2022, 140 : 10182 - 10184
[44] MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Grosicki, Sebastian
Crafoord, Jacob
Koh, Youngil
White, Darrel
Mellqvist, Ulf-Henrik
Leip, Eric
Kudla, Arthur
Finn, Gregory
Pruchniewski, Lukasz
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[45] Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma
Lust, John A.
Usmani, Saad Z.
Hamadani, Mehdi
Barranco, Charles
Lacy, Martha Q.
Dispenzieri, Angela
Gertz, Morie A.
Dingli, David
Russell, Stephen
Buadi, Francis K.
Zeldenrust, Steven R.
Hayman, Suzanne R.
Rajkumar, S. Vincent
Kumar, Shaji K.
Thompson, John
Taylor, Catherine A.
Dondero, Richard
BLOOD, 2012, 120 (21)
[46] An open-label, multicenter, phase Ib study of daratumumab in combination with backbone regimens in patients with multiple myeloma
Comenzo, Raymond
Moreau, Philippe
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
de la Rubia, Javier
Facon, Thierry
Fay, Joseph
Qin, Xiang
Masterson, Tara
Schecter, Jordan
Ahmadi, Tahamtan
San-Miguel, Jesus
CANCER RESEARCH, 2015, 75
[47] Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study
Grammatico, Sara
Bringhen, Sara
Vozella, Federico
Siniscalchi, Agostina
Boccadoro, Mario
Petrucci, Maria Teresa
LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2738 - 2740
[48] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study
Plesner, Torben
Arkenau, Hendrik-Tobias
Gay, Francesca Marianatal
Minnema, Monique C.
Boccadoro, Mario
Moreau, Philippe
Cavenagh, James D.
Perrot, Aurore
Laubach, Jacob
Ahmadi, Tahamtan
de Boer, Carla
Chen, Diana
Chiu, Christopher
Schecter, Jordan
Richardson, Paul G.
BLOOD, 2017, 130
[49] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
Jacob P. Laubach
Sascha A. Tuchman
Jacalyn M. Rosenblatt
Constantine S. Mitsiades
Kathleen Colson
Kelly Masone
Diane Warren
Robert A. Redd
Dena Grayson
Paul G. Richardson
Blood Cancer Journal, 11
[50] UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB (OPZ) IN PATIENTS (PTS) WITH HEMATOLOGIC MALIGNANCIES, INCLUDING MULTIPLE MYELOMA (MM)
Vij, R.
Savona, M.
Siegel, D.
Kaufman, J. L.
Badros, A.
Ghobrial, I.
Paner, A.
Jagannath, S.
Jakubowiak, A.
Mikhael, J.
Kapoor, P.
Neuman, L.
Obreja, M.
Berdeja, J.
HAEMATOLOGICA, 2015, 100 : 251 - 251

← 1 2 3 4 5 →